Skip to content

CLOPAM® · For mRNA & vaccine developers

Your vaccine.Into the skin.Precisely.

mRNA has changed what a vaccine can do. The skin is where the immune system pays closest attention — and CLOPAM places every dose there, aseptically, needle by needle.
Intradermal dose authorized to stretch a vaccine supply up to five-fold
1/5Intradermal dose authorized to stretch a vaccine supply up to five-fold
Infants seroconverted to measles with a microneedle patch
93%Infants seroconverted to measles with a microneedle patch
Needles, sharps or trained injectors
0Needles, sharps or trained injectors

01 — The breakthroughs

mRNA has changed what a vaccine can do.

Each new result raises the same question: where, and how precisely, the dose lands.
  • Personalized cancer vaccines

    49%

    lower risk of recurrence or death at five years when an individualized mRNA neoantigen therapy was added to a checkpoint inhibitor in resected high-risk melanoma (randomized phase IIb).

    Khattak A et al. J Clin Oncol 2026;44:2482–9

  • T cells that last

    7.7 yrs

    average estimated lifespan of the CD8 T-cell clones an individualized mRNA vaccine induced in pancreatic cancer; responders stayed recurrence-free far longer (phase 1).

    Sethna Z et al. Nature 2025;639:1042–51

  • Doses keep shrinking

    5 µg

    per dose for the first self-amplifying mRNA vaccine authorized in the EU (2025) — a fraction of first-generation mRNA doses. Every microgram saved makes room for a smaller, simpler format.

    European Medicines Agency, product information (2025)

02 — Why the skin

The skin is the immune system's front door.

Muscle is where vaccines are usually injected. The skin is where antigen-presenting cells wait for them.

Dense with immune sentinels

The epidermis and upper dermis are packed with Langerhans cells and dermal dendritic cells that capture antigen and carry it to the lymph nodes. Muscle has far fewer. Put the dose in the skin and less of it can do the same work.

Kim YC, Park JH, Prausnitz MR. Adv Drug Deliv Rev 2012;64:1547–68

Dose-sparing

Stretch scarce or costly antigen and mRNA in an outbreak or a launch.

T-cell responses

Dendritic cells in the skin prime the T cells cancer and viral vaccines depend on.

Gentler on the body

Smaller doses with fewer systemic side effects in intradermal studies.

03 — Patches already work

Microneedle patches already vaccinate people.

Clinical trials have shown it works. They have also shown that precision decides the result.
  1. 01

    Influenza, adults

    ≈ IM

    A dissolvable microneedle patch matched intramuscular antibody titres for all three strains — including when people applied it themselves. Well tolerated.

    Rouphael NG et al. Lancet 2017;390:649–58

  2. 02

    Measles–rubella, infants

    93% · 100%

    measles and rubella seroconversion in 9–10-month-old infants with a patch, against 90% and 100% by injection. No related severe or serious adverse events.

    Adigweme I et al. Lancet 2024;403:1879–92

  3. 03

    mRNA in a patch

    6 months

    mRNA-lipid nanoparticle patches stayed shelf-stable for at least six months at room temperature (model mRNA); in mice, responses matched intramuscular injection. Preclinical.

    Vander Straeten A et al. Nat Biotechnol 2024;42:510–7

Not every patch delivers

A needle-free nanoporous patch given an mRNA booster raised no antibody or T-cell response at all. The field's own reviews name sterility assurance, dose uniformity and nucleic-acid integrity as the hurdles left.

Prins MLM et al. Virus Res 2023;334:199175 Nguyen HX et al. Pharmaceutics 2026;18:1022

04 — Why CLOPAM

Built for exactly those hurdles.

  • Aseptic, needle by needle

    Each patch stays sealed in its own mold until use — sterility assurance built into the format, not added after it.

  • Dose where immunity starts

    Patented aero-pressure drying concentrates the antigen or mRNA in the needle tips, which dissolve in the epidermis and dermis.

  • A dose you can count on

    A fixed dose per patch and a pressure-activated applicator for consistent, uniform application, confirmed by a click.

  • Dry and sealed

    A solid, dissolving matrix kept from moisture in hermetic packaging — a route toward a lighter cold chain.

  • Self-applied, no sharps

    No trained injector and nothing sharp to dispose of: built for mass campaigns and outbreak response.

  • No needle to fear

    A painless patch can win over people who put vaccines off.

  • Already in vaccines

    A CLOPAM influenza vaccine is in preclinical development.

  • Made aseptically at scale

    The world's first fully aseptic microneedle patch plant runs in Hyangnam, with a large-scale commercial plant to follow.

Put your vaccine where immunity starts.

Send us your antigen or mRNA-LNP under an MTA. We'll come back with patch feasibility data — loading, stability and delivery into the skin.

Test your vaccine

Results cited on this page come from published studies of other vaccines and devices, not from CLOPAM. CLOPAM's influenza vaccine is in preclinical development; performance with any antigen or mRNA is confirmed in development.